Targeting chronic conditions such as diabetes, cardiovascular disease and osteoporosis, the Regenstrief Institute and Merck have signed a five-year agreement that will see them collaborating on novel ways to use clinical data to inform personalized delivery of healthcare.
The partnership will seek to deploy data analytics and other innovations to support evidence-based healthcare. Financial details were not disclosed.
“Regenstrief has a passion for determining how personalization of medicine can be achieved by better understanding and using health data,” said Regenstrief investigator and innovations officer Jon Duke, MD, an assistant professor of medicine at the Indiana University School of Medicine who's also the institute’s lead investigator for the partnership.
"This type of novel academic-industry collaboration can advance our understanding of a number of critical therapeutic areas, enabling novel use of health information technology to enhance drug development, medication safety and the personalization of therapeutics," said Sachin H. Jain, MD, chief medical information and innovation officer at Merck.
“Regenstrief brings rigorous science to clinical environments and has more than 40 years of experience as an international leader in improving health care delivery through informatics and health services research," said Duke. "With Merck’s depth of expertise and its global reach, we hope to develop and test new approaches to care, and advance successful models of health care broadly.”